The departure of Pascal Soriot from Roche’s pharmaceutical division to the helm of rival AstraZeneca comes as a surprise, but the move isn’t likely to leave a hole among the higher ranks of the Swiss drug maker.
Roche veteran Daniel O’Day, who was tapped to replace Mr. Soriot as the new head of the Roche’s flagship pharmaceutical division, is well-equipped for the job. He’s held various positions at the unit since 1987 and spent his entire career at Roche, including postings in the U.S. and Japan. Most recently, Mr. O’Day, an American national, spent six years at Roche’s diagnostics division, leading it as chief operating officer since 2010.
Read the full story: http://tinyurl.com/9e2z5px
Source: The Wall Street Journal